If Pegusus is bringing in some decent cash right now, does it make sense for Roche to do an all oral antiviral cocktail trial so they can lose that Pegusus revenue? Pharma companies are to maximize shareholder values rather than to create a better treatment option for patients.
Market Data 
Markets 
AI
